An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
<p>Abstract</p> <p>Background</p> <p>The Apo-1/Fas (CD95) molecule is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor (TNF) receptor family. Both Fas and Fas ligand (FasL) are expressed in activated mature T cells, and prolonged cell...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2002-08-01
|
| Series: | BMC Neurology |
| Online Access: | http://www.biomedcentral.com/1471-2377/2/8 |
| _version_ | 1818355374280933376 |
|---|---|
| author | Yabe Ichiro Miyagishi Ryuji Fukazawa Toshiyuki Kikuchi Seiji Niino Masaaki Tashiro Kunio |
| author_facet | Yabe Ichiro Miyagishi Ryuji Fukazawa Toshiyuki Kikuchi Seiji Niino Masaaki Tashiro Kunio |
| author_sort | Yabe Ichiro |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The Apo-1/Fas (CD95) molecule is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor (TNF) receptor family. Both Fas and Fas ligand (FasL) are expressed in activated mature T cells, and prolonged cell activation induces susceptibility to Fas-mediated apoptosis. The Apo-1/Fas gene is located in a chromosomal region that shows linkage in multiple sclerosis (MS) genome screens, and studies indicate that there is aberrant expression of the Apo-1/Fas molecule in MS.</p> <p>Methods</p> <p>Mva I polymorphism on the Apo-1/Fas promoter gene was detected by PCR-RFLP from the DNA of 114 Japanese patients with conventional MS and 121 healthy controls. We investigated the association of the Mva I polymorphism in Japanese MS patients using a case-control association study design.</p> <p>Results</p> <p>We found no evidence that the polymorphism contributes to susceptibility to MS. Furthermore, there was no association between Apo-1/Fas gene polymorphisms and clinical course (relapsing-remitting course or secondary-progressive course). No significant association was observed between Apo-1/Fas gene polymorphisms and the age at disease onset.</p> <p>Conclusions</p> <p>Overall, our findings suggest that Apo-1/Fas promoter gene polymorphisms are not conclusively related to susceptibility to MS or the clinical characteristics of Japanese patients with MS.</p> |
| first_indexed | 2024-12-13T19:40:18Z |
| format | Article |
| id | doaj.art-086c7cd5c6c24233851822cb88476d69 |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-12-13T19:40:18Z |
| publishDate | 2002-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-086c7cd5c6c24233851822cb88476d692022-12-21T23:33:42ZengBMCBMC Neurology1471-23772002-08-0121810.1186/1471-2377-2-8An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosisYabe IchiroMiyagishi RyujiFukazawa ToshiyukiKikuchi SeijiNiino MasaakiTashiro Kunio<p>Abstract</p> <p>Background</p> <p>The Apo-1/Fas (CD95) molecule is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor (TNF) receptor family. Both Fas and Fas ligand (FasL) are expressed in activated mature T cells, and prolonged cell activation induces susceptibility to Fas-mediated apoptosis. The Apo-1/Fas gene is located in a chromosomal region that shows linkage in multiple sclerosis (MS) genome screens, and studies indicate that there is aberrant expression of the Apo-1/Fas molecule in MS.</p> <p>Methods</p> <p>Mva I polymorphism on the Apo-1/Fas promoter gene was detected by PCR-RFLP from the DNA of 114 Japanese patients with conventional MS and 121 healthy controls. We investigated the association of the Mva I polymorphism in Japanese MS patients using a case-control association study design.</p> <p>Results</p> <p>We found no evidence that the polymorphism contributes to susceptibility to MS. Furthermore, there was no association between Apo-1/Fas gene polymorphisms and clinical course (relapsing-remitting course or secondary-progressive course). No significant association was observed between Apo-1/Fas gene polymorphisms and the age at disease onset.</p> <p>Conclusions</p> <p>Overall, our findings suggest that Apo-1/Fas promoter gene polymorphisms are not conclusively related to susceptibility to MS or the clinical characteristics of Japanese patients with MS.</p>http://www.biomedcentral.com/1471-2377/2/8 |
| spellingShingle | Yabe Ichiro Miyagishi Ryuji Fukazawa Toshiyuki Kikuchi Seiji Niino Masaaki Tashiro Kunio An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis BMC Neurology |
| title | An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis |
| title_full | An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis |
| title_fullStr | An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis |
| title_full_unstemmed | An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis |
| title_short | An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis |
| title_sort | examination of the apo 1 fas promoter mva i polymorphism in japanese patients with multiple sclerosis |
| url | http://www.biomedcentral.com/1471-2377/2/8 |
| work_keys_str_mv | AT yabeichiro anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT miyagishiryuji anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT fukazawatoshiyuki anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT kikuchiseiji anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT niinomasaaki anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT tashirokunio anexaminationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT yabeichiro examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT miyagishiryuji examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT fukazawatoshiyuki examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT kikuchiseiji examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT niinomasaaki examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis AT tashirokunio examinationoftheapo1faspromotermvaipolymorphisminjapanesepatientswithmultiplesclerosis |